- Home
- JSPR vs SGHT Comparison
JSPR vs SGHT Comparison
Compare JSPR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- SGHT
- Stock Information
- Founded
- JSPR 2018
- SGHT 2011
- Country
- JSPR United States
- SGHT United States
- Employees
- JSPR N/A
- SGHT N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- SGHT Medical Specialities
- Sector
- JSPR Health Care
- SGHT Health Care
- Exchange
- JSPR Nasdaq
- SGHT Nasdaq
- Market Cap
- JSPR 325.7M
- SGHT 304.4M
- IPO Year
- JSPR N/A
- SGHT 2021
- Fundamental
- Price
- JSPR $21.71
- SGHT $3.55
- Analyst Decision
- JSPR Strong Buy
- SGHT Buy
- Analyst Count
- JSPR 11
- SGHT 7
- Target Price
- JSPR $73.38
- SGHT $6.27
- AVG Volume (30 Days)
- JSPR 184.2K
- SGHT 218.9K
- Earning Date
- JSPR 11-07-2024
- SGHT 11-07-2024
- Dividend Yield
- JSPR N/A
- SGHT N/A
- EPS Growth
- JSPR N/A
- SGHT N/A
- EPS
- JSPR N/A
- SGHT N/A
- Revenue
- JSPR N/A
- SGHT $79,543,000.00
- Revenue This Year
- JSPR N/A
- SGHT $2.13
- Revenue Next Year
- JSPR N/A
- SGHT $7.99
- P/E Ratio
- JSPR N/A
- SGHT N/A
- Revenue Growth
- JSPR N/A
- SGHT N/A
- 52 Week Low
- JSPR $5.02
- SGHT $3.30
- 52 Week High
- JSPR $31.01
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- JSPR 49.34
- SGHT 39.11
- Support Level
- JSPR $20.77
- SGHT $3.30
- Resistance Level
- JSPR $23.11
- SGHT $3.64
- Average True Range (ATR)
- JSPR 1.67
- SGHT 0.20
- MACD
- JSPR -0.08
- SGHT 0.02
- Stochastic Oscillator
- JSPR 51.34
- SGHT 30.67
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.